Evidence
J Clin Exp Hepatol. 2024 Mar-Apr;14(2):101288. doi: 10.1016/j.jceh.2023.09.009. Epub 2023 Sep 28.
ABSTRACT
BACKGROUND: Transient infantile hypertriglyceridemia (TIH) is a syndrome of hypertriglyceridemia, fatty liver, and deranged liver functions with progression to fibrosis and cirrhosis. It is an autosomal recessive disorder caused by mutations in Glycerol-3-phosphate dehydrogenase 1 gene present on Chromosome 12q12-q13, and has been reported in Israeli Arab families with high consanguinity. TIH is suspected by high serum triglyceride levels and steatosis on liver biopsy; however, diagnosis is confirmed on clinical exome sequencing.
CLINICAL DESCRIPTION: We present two cases of TIH belonging to the indigenous Hindu, hilly population of Himachal Pradesh in North India with no history of either consanguinity or family history.
MANAGEMENT AND OUTCOME: The parents of both the cases were counselled regarding the disease and importance of growth and lipid level monitoring.
CONCLUSION: Though TIH is an extremely rare entity, awareness about it is required as it is a contributor to non-alcoholic fatty liver disease (NAFLD) in children. Any child presenting with hepatomegaly and elevated fasting triglyceride levels should be further investigated for TIH.
PMID:38076448 | PMC:PMC10709506 | DOI:10.1016/j.jceh.2023.09.009
Estimated reading time: 4 minute(s)
Latest: Psychiatryai.com #RAISR4D Evidence
Cool Evidence: Engaging Young People and Students in Real-World Evidence
Real-Time Evidence Search [Psychiatry]
AI Research
A Novel cause of Massive Hepatosplenomegaly with Fibrosis in two children: Transient Infantile Hypertriglyceridemia
🌐 90 Days
AI Virtual Reality Related Evidence Matrix
- Long-term clinical outcomes and management of hypertriglyceridemia in children with Apo-CII deficiency
- A Validation Study of Non-invasive Scoring Systems for Assessing Severity of Hepatic Fibrosis in a Cohort of South Indian Patients With Non-alcoholic Fatty Liver Disease
- Galectin-3 and Severity of Liver Fibrosis in Metabolic Dysfunction-Associated Fatty Liver Disease
- Recruitment or activation of mast cells in the liver aggravates the accumulation of fibrosis in carbon tetrachloride-induced liver injury
- Examining the Role of Self-Harm in the Relationship between Emergency Department Service Utilization and Trauma-Induced Homelessness among Homeless Individuals in Texas
- Serum miR‑29 is increased in mice with early liver fibrosis
- EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)
- Coexistence of metabolic-associated fatty liver disease and autoimmune or toxic liver disease
- Comparative and Predictive Significance of Serum Leptin Levels in Non-alcoholic Fatty Liver Disease
- The Influence of Emodin Succinyl Ethyl Ester on Non-Alcoholic Steatohepatitis Induced by a Diet High in Fructose, Cholesterol, and Fat in Mice
- Managing hypertriglyceridemia for cardiovascular disease prevention: Lessons from the PROMINENT trial
- Progress of mesenchymal stem cells (MSCs) & MSC-Exosomes combined with drugs intervention in liver fibrosis
- Non-invasive Scores and Serum Biomarkers for Fatty Liver in the Era of Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD): A Comprehensive Review From NAFLD to MAFLD and MASLD
- Non-invasive Scores and Serum Biomarkers for Fatty Liver in the Era of Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD): A Comprehensive Review From NAFLD to MAFLD and MASLD
- Liver histology is associated with long-term clinical outcomes in patients with metabolic dysfunction-associated steatohepatitis
- Roflumilast ameliorates GAN diet-induced non-alcoholic fatty liver disease by reducing hepatic steatosis and fibrosis in ob/ob mice
- Quantitative measurements of M2BPGi depend on liver fibrosis and inflammation
- Quantitative measurements of M2BPGi depend on liver fibrosis and inflammation
- RNA modifications in the progression of liver diseases: from fatty liver to cancer
- RNA modifications in the progression of liver diseases: from fatty liver to cancer
- Abnormal liver steatosis and fibrosis serum biomarker levels among psychiatric inpatients
- Abnormal liver steatosis and fibrosis serum biomarker levels among psychiatric inpatients
- Coronary artery disease as a risk factor for metabolic dysfunction-associated steatotic liver disease and liver fibrosis
- The protective effects of Ninjin'yoeito against liver steatosis/fibrosis in a non-alcoholic steatohepatitis model mouse
- Association of Histopathological and Biochemical Aspects of NAFLD With the Severity of Liver Fibrosis in Individuals With Obesity: Cross-sectional Study
- Protective role of 17b-estradiol in alcohol-associated liver fibrosis is mediated by suppression of integrin signaling
- Use of PNPLA3, TM6SF2, and HSD17B13 for detection of fibrosis in MASLD in the general population
- Clinical features of individuals with laboratory values suggestive of advanced liver fibrosis when first treated for alcohol use disorder
- Chronic unpredictable mild stress increases serum aldosterone without affecting corticosterone levels and induces hepatic steatosis and renal injury in young adult male rats
- Antidepressants in People With Chronic Liver Disease and Depression: When Are They Warranted and How to Choose the Suitable One?
- Serum autotaxin is a prognostic indicator of liver-related events in patients with non-alcoholic fatty liver disease
- Probiotic supplementation for 24 weeks in patients with non-alcoholic steatohepatitis: the PROBILIVER randomized clinical trial
- THE GLOBAL EPIDEMIOLOGY OF NON-ALCOHOLIC FATTY LIVER DISEASE AND NON-ALCOHOLIC STEATOHEPATITIS AMONG PATIENTS WITH TYPE 2 DIABETES
- Analysis of non-alcoholic fatty liver disease differences from metabolic dysfunction-associated fatty liver disease based on clinical features
- Efficacy and Safety of Aldafermin in Non-Alcoholic Steatohepatitis: A systematic review and meta-analysis of randomized controlled trials
- Association between the cardiometabolic index and NAFLD and fibrosis
- White Adipose Tissue in Metabolic Associated Fatty Liver Disease
- Multiscale 3D genome organization underlies duck fatty liver with no adipose inflammation or serious injury
- Resmetirom, the long-awaited first treatment for metabolic dysfunction-associated steatohepatitis and liver fibrosis?
- Liver fibrosis is associated with left ventricular remodeling: insight into the liver-heart axis
- Clinicopathological features of Sjogren's syndrome complicated with liver injury
- CD47, a novel YAP target gene, contributes to hepatic stellate cell activation and liver fibrosis induced by high-fat diet
- Angiocrine signaling in sinusoidal homeostasis and liver diseases
- Epigenetic modification in liver fibrosis: Promising therapeutic direction with significant challenges ahead
- The diagnostic utility of FIB-4 as a non-invasive tool for liver fibrosis scoring among NAFLD patients: a retrospective cross-sectional study
- Role of lactate and lactate metabolism in liver diseases (Review)
- Interaction between fatty acid oxidation and ethanol metabolism in liver
- Effects of Ganjianglingzhu Decoction on Lean Non-Alcoholic Fatty Liver Disease in Mice Based on Untargeted Metabolomics
- Vitamin D(3) exacerbates steatosis while calcipotriol inhibits inflammation in non-alcoholic fatty liver disease in Sod1 knockout mice: a comparative study of two forms of vitamin D
- The Diagnostic Value of Liver Biopsy for Unexplained Liver Dysfunction: A Retrospective Study
- The Diagnostic Value of Liver Biopsy for Unexplained Liver Dysfunction: A Retrospective Study
- COVID-19 in Individuals with Chronic Liver Diseases
- Imbalance of mitochondrial fusion in peripheral blood mononuclear cells is associated with liver fibrosis in patients with metabolic dysfunction-associated steatohepatitis
- A Prospective Randomised Comparative Four-arm Intervention Study of Efficacy and Safety of Saroglitazar and Vitamin E in Patients With Non-alcoholic Fatty Liver Disease (NAFLD)/Non-alcoholic Steatohepatitis (NASH)-SVIN TRIAL
- Spleen volume is independently associated with non-alcoholic fatty liver disease, liver volume and liver fibrosis
- Alcohol use disorders and liver fibrosis: an update
- The fatty acid omega hydroxylase genes (CYP4 family) in the progression of metabolic dysfunction-associated steatotic liver disease (MASLD): An RNA sequence database analysis and review
- From NAFLD to NASH: Understanding the spectrum of non-alcoholic liver diseases and their consequences
- The role of PI3k/AKT signaling pathway in attenuating liver fibrosis: a comprehensive review
- Iron metabolism and ferroptosis in Non-alcoholic fatty liver disease: what is our next step?
- The association between diverse serum folate with MAFLD and liver fibrosis based on NHANES 2017-2020
- Anxiety and depression in metabolic-associated steatotic liver disease: relation with socio-demographic features and liver disease severity
- Muscle Quality as a Potential Diagnostic Marker of Advanced Liver Fibrosis in Patients with Non-alcoholic Fatty Liver Disease
- Nonalcoholic Fatty Liver Disease and Ethnicity: Lessons Learned from the Arab Population in Israel
Evidence Blueprint
A Novel cause of Massive Hepatosplenomegaly with Fibrosis in two children: Transient Infantile Hypertriglyceridemia
☊ AI-Driven Related Evidence Nodes
(recent articles with at least 5 words in title)
More Evidence
A Novel cause of Massive Hepatosplenomegaly with Fibrosis in two children: Transient Infantile Hypertriglyceridemia
🌐 365 Days
AI Virtual Reality Related Evidence Matrix
- A Form of Metabolic-Associated Fatty Liver Disease Associated with a Novel LIPA Variant
- Severe Acute Liver Injury: First Manifestation of Systemic Lupus Erythematosus
- Diagnostic Accuracy of Vibration Controlled Transient Elastography as Non-invasive Assessment of Liver Fibrosis in Patients with Non-alcoholic Fatty Liver Disease
- Increased frequency of hepatic steatosis and fibrosis in patients with gout detected by transient elastography
- Transient Elastography Is the Best-Performing Non-Invasive Test of Liver Fibrosis in Obese Asian Patients with Non-Alcoholic Fatty Liver Disease: A Pilot, Cross-Sectional Study
- Factors Associated with Discordance in the Assessment of Fibrosis Stage between Transient Elastography and Liver Biopsy in NAFLD Patients
- Long-term clinical outcomes and management of hypertriglyceridemia in children with Apo-CII deficiency
- A Validation Study of Non-invasive Scoring Systems for Assessing Severity of Hepatic Fibrosis in a Cohort of South Indian Patients With Non-alcoholic Fatty Liver Disease
- Galectin-3 and Severity of Liver Fibrosis in Metabolic Dysfunction-Associated Fatty Liver Disease
- Performance of FibroScan in grading steatosis and fibrosis in patients with nonalcoholic fatty liver disease: A meta-analysis
- NAFLD is associated with less severe liver fibrosis in chronic hepatitis B: a multi-center, retrospective study
- Recruitment or activation of mast cells in the liver aggravates the accumulation of fibrosis in carbon tetrachloride-induced liver injury
- The Value of Liver Biopsy and Histology in Liver Disease Diagnosis and Patient Care-a Pragmatic Prospective Clinical Practice Study
- Post-transplant Non-alcoholic Fatty Liver Disease and Metabolic Syndrome After Living Donor Liver Transplantation in Indians
- Non-Invasive Measurement of Hepatic Fibrosis by Transient Elastography: A Narrative Review
- A Markov model of fibrosis development in Non-Alcoholic Fatty Liver Disease predicts fibrosis progression in clinical cohorts
- Examining the Role of Self-Harm in the Relationship between Emergency Department Service Utilization and Trauma-Induced Homelessness among Homeless Individuals in Texas
- Serum miR‑29 is increased in mice with early liver fibrosis
- Fatty liver is associated with significant liver inflammation and increases the burden of advanced fibrosis in chronic HBV infection
- Diagnostic Performance of Quantitative Ultrasound Parameters in Non-alcoholic Fatty Liver Disease
- EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)
- Liver fat as risk factor of hepatic and cardiometabolic diseases
- Coexistence of metabolic-associated fatty liver disease and autoimmune or toxic liver disease
- ALT Poorly Predicts Nonalcoholic Fatty Liver Disease (NAFLD) and Liver Fibrosis as Determined by Vibration-Controlled Transient Elastography in Adult National Health and Nutrition Examination Survey 2017-2018: ALT Poorly Predicts NAFLD and…
- Comparative and Predictive Significance of Serum Leptin Levels in Non-alcoholic Fatty Liver Disease
- The Influence of Emodin Succinyl Ethyl Ester on Non-Alcoholic Steatohepatitis Induced by a Diet High in Fructose, Cholesterol, and Fat in Mice
- Lipid disorders before and after successful liver transplantation
- Cost-effectiveness analysis of noninvasive tests to identify advanced fibrosis in non-alcoholic fatty liver disease
- A Girl with PRRT2 Mutation Presenting with Benign Familial Infantile Seizures Followed by Autistic Regression
- Higher ultra-processed food intake is associated with adverse liver outcomes: a prospective cohort study of UK Biobank participants
- ALCOHOLIC FOAMY DEGENERATION, AN ENTITY RESEMBLING ALCOHOL-ASSOCIATED HEPATITIS: DIAGNOSIS, PROGNOSIS AND MOLECULAR PROFILING
- Progress in the Correlation Between Inflammasome NLRP3 and Liver Fibrosis
- Successful Recovery from Severe Alcoholic Hepatitis (SAH) for Third Time
- A Hospital Based Observational Study to Detect Non-Alcoholic Steatohepatitis by Acoustic Radiation Force Impulse in Individuals with Diabetes Mellitus and Metabolic Syndrome
- Liver fibrosis screening, evaluation pathway, and management in patients with fatty liver
- Hepatic Fibrosis and Cancer: The Silent Threats of Metabolic Syndrome
- Crohn´s disease is an independent risk factor for liver fibrosis in patients with inflammatory bowel disease and non-alcoholic fatty liver disease
- High prevalence of de novo metabolic dysfunction-associated fatty liver disease after liver transplantation and the role of controlled attenuation parameter
- Metabolic dysfunction-associated steatotic liver disease: Where does non-alcoholic fatty liver disease in liver transplant recipients fit in this new definition?
- NASH After Liver Transplantation: Impact of Immunosuppression
- Metabolic study of iron deposition based on magnetic resonance in patients with nonalcoholic fatty liver disease
- The Interrelation Between Hypothyroidism and Non-alcoholic Fatty Liver Disease, a Cross-sectional Study
- Interactions between the metabolic syndrome and alcohol consumption increases the risk of liver disease
- Managing hypertriglyceridemia for cardiovascular disease prevention: Lessons from the PROMINENT trial
- AN1284 attenuates steatosis, lipogenesis, and fibrosis in mice with pre-existing non-alcoholic steatohepatitis and directly affects aryl hydrocarbon receptor in a hepatic cell line
- Liver Transplantation in Chronic Liver Disease and Acute on Chronic Liver Failure- Indication, Timing and Practices
- Liver Transplantation in Chronic Liver Disease and Acute on Chronic Liver Failure- Indication, Timing and Practices
- Progress of mesenchymal stem cells (MSCs) & MSC-Exosomes combined with drugs intervention in liver fibrosis
- ABDA Score: A Non-invasive Model to Identify Subjects with Fibrotic Non-alcoholic Steatohepatitis in the Community
- Non-invasive Scores and Serum Biomarkers for Fatty Liver in the Era of Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD): A Comprehensive Review From NAFLD to MAFLD and MASLD
- Non-invasive Scores and Serum Biomarkers for Fatty Liver in the Era of Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD): A Comprehensive Review From NAFLD to MAFLD and MASLD
- Liver histology is associated with long-term clinical outcomes in patients with metabolic dysfunction-associated steatohepatitis
- Research progress of celastrol on the prevention and treatment of metabolic associated fatty liver disease
- Screening, Diagnosis, and Staging of Non-Alcoholic Fatty Liver Disease (NAFLD): Application of Society Guidelines to Clinical Practice
- Global incidence of adverse clinical events in non-alcoholic fatty liver disease: A systematic review and meta-analysis
- Biomarkers of liver diseases
- Identifying a distinct fibrosis subset of NAFLD via molecular profiling and the involvement of profibrotic macrophages
- Analysis of clinical features and identification of risk factors in patients with non-alcoholic fatty liver disease based on FibroTouch
- Corrected and republished from: Metabolic associated liver disease
- Roflumilast ameliorates GAN diet-induced non-alcoholic fatty liver disease by reducing hepatic steatosis and fibrosis in ob/ob mice
- FIB-4 is closer to FibroScan screen results to detecting advanced liver fibrosis and maybe facilitates NAFLD warning
- Role of microRNA in non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH): a comprehensive review
- Epidemiology and risk factors for histopathologic characteristics of non-alcoholic fatty liver disease in South America
- Quantitative measurements of M2BPGi depend on liver fibrosis and inflammation